ClinicalTrials.gg
CompletedNCT03013543Updated Aug 18, 2023Results posted

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

A Phase 2 interventional study of Setmelanotide in Genetic Obesity, Obesity and Obesity Due to Melanocortin 4 Receptor Deficiency, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 58 sites in 9 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2023-08-18.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
213
Allocation
Non-randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.

Enrollment
2nd of 16
213 · median 34
Started
2017
with 2 others
Phase 2
6 of 16
1 open now
Registered
6th of 16
by date
Lead sponsor
15 of 16
Rhythm Pharmaceuticals, Inc.

Among the 16 studies testing setmelanotide in Obesity, this one is the 2nd largest by enrollment, is one of 3 that started in 2017, is one of 6 in phase 2, and was the 6th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About setmelanotide

setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing setmelanotide in Obesity, or all of them as a file.
02

Study summary

The purpose of the study was to determine the effect of setmelanotide (RM-493) on weight, hunger assessments, and other factors in participants with rare genetic disorders of obesity.

03

Conditions studied

  • Genetic Obesity
  • Obesity
  • Obesity Due to Melanocortin 4 Receptor Deficiency

Browse trials for

Keywords

  • Pro-opiomelanocortin (POMC) deficiency obesity
  • LepR deficiency obesity
  • Smith-Magenis Syndrome
  • MC4R deficiency obesity
  • SRC1 deficiency obesity
  • SH2B1 deficiency obesity
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Participants with the following genotypes and/or clinical assessment:

    1. POMC/PCSK1/LEPR heterozygous - not currently enrolling new participants
    2. POMC/PCSK1/LEPR compound heterozygous (two different mutations in gene) or homozygous deficiency obesity
    3. POMC/PCSK1/LEPR composite heterozygous (two or more mutations in two or more genes) deficiency obesity
    4. SMS
    5. SH2B1 deficiency obesity
    6. Chromosomal rearrangement of the 16p11.2 locus causing obesity
    7. Carboxypeptidase E (CPE) compound heterozygous or homozygous deficiency obesity
    8. Leptin deficiency obesity with loss of response to metreleptin
    9. SRC1 deficiency obesity
    10. MC4R deficiency obesity
  2. Age 6 years and above
  3. Obese, defined as (BMI) ≥ 30 kilogram per meter square (kg/m\^2) for participants ≥16 years of age or BMI≥ 95th percentile for age and gender for participants 6 up to 16 years of age.
  4. Participant and/or parent or guardian is able to understand and comply with the requirements of the study and is able to understand and sign the written /assent
  5. Female participants of must be confirmed non-pregnant, and agree to use as outlined in the protocol.
  6. Male participants with female partners of childbearing potential must agree to a double barrier method if they become sexually active during the study. Male participants must not donate sperm during and for 90 days following their participation in the study.

Key Exclusion Criteria:

  1. Recent intensive (within 2 months) diet and/or exercise regimen with or without the use of weight loss agents that has resulted in > 2% weight loss.
  2. Use of any medication that is approved to treat obesity within three months of first dose of study drug (e.g., orlistat, lorcaserin, phentermine-topiramate, naltrexone-bupropion).
  3. Gastric bypass surgery within the previous six months or any prior gastric bypass surgery resulting in >10% weight loss durably maintained
  4. Diagnosis of schizophrenia, bipolar disorder, personality disorder, major depressive disorder, or other psychiatric disorder(s)
  5. Suicidal ideation, attempt or behavior
  6. pulmonary, cardiac, or oncologic disease
  7. (HbA1c) > 9.0% at Screening
  8. History of significant liver disease
  9. (GFR) \< 30 milliliter/minute (mL/min) at Screening.
  10. History or close family history of melanoma or participant history of oculocutaneous albinism
  11. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions.
  12. Participation in any clinical study with an drug/device within 3 months prior to the first day of dosing.
  13. Participants previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide.
  14. Inability to comply with QD injection regimen.
  15. Females who are breastfeeding or nursing.

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
213 participants (actual)

Study arms

  • Experimental
    16p11.2 Cohort

    Participants with chromosomal rearrangement of the p11.2 region of chromosome 16 (16p11.2) locus causing obesity received setmelanotide once daily (QD) via subcutaneous (SC) injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.

    Drug: Setmelanotide

  • Experimental
    AS Cohort

    Participants with Alström syndrome (AS) received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.

    Drug: Setmelanotide

  • Experimental
    BBS Cohort

    Participants with Bardet-Biedl syndrome (BBS) received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.

    Drug: Setmelanotide

  • Experimental
    MC4R Cohort

    Participants with melanocortin-4 receptor (MC4R) deficiency obesity received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.

    Drug: Setmelanotide

  • Experimental
    POMC/PCSK1/LEPR Heterozygous Cohort

    Participants with pro-opiomelanocortin (POMC)/proprotein convertase subtilisin/kexin type 1 (PCSK1)/leptin receptor (LEPR) heterozygous mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.

    Drug: Setmelanotide

  • Experimental
    POMC/PCSK1/LEPR Composite Heterozygous Cohort

    Participants with POMC/PCSK1/LEPR composite heterozygous mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.

    Drug: Setmelanotide

  • Experimental
    POMC/PCSK1/LEPR Compound Heterozygous Cohort

    Participants with POMC/PCSK1/LEPR compound heterozygous mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.

    Drug: Setmelanotide

  • Experimental
    SH2B1 Cohort

    Participants with steroid receptor coactivator (SRC) homology 2B adapter protein 1 (SH2B1) haploinsufficiency received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.

    Drug: Setmelanotide

  • Experimental
    SMS Cohort

    Participants with Smith-Magenis Syndrome (SMS) received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.

    Drug: Setmelanotide

  • Experimental
    SRC1 Cohort

    Participants with steroid receptor coactivator 1 (SRC1) mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.

    Drug: Setmelanotide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment

    Time frame: Baseline to Month 3

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE (also referred to as an adverse experience) could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. TEAEs were defined as AEs reported after dosing on Day 1.

    Time frame: From first dose up to Month 16

  2. Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment

    Time frame: Baseline, Month 3

  3. Percent Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment

    Time frame: Baseline, Month 3

  4. Change From Baseline in Daily Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged ≥ 12 Years

    The mean change in daily hunger questionnaire scores for participants ≥ 12 years of age with obesity in treatment with setmelanotide was evaluated. On the Daily Hunger Questionnaire, each of the 3 items (average hunger in the last 24 hours, most/worst hunger in the last 24 hours, and morning hunger) was assessed daily and scored separately using a numeric rating score for each from 0 to 10, with 0 = not hungry at all and 10 = hungriest possible.

    Time frame: Baseline, Month 3

  5. Change From Baseline in Daily Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged < 12 Years

    The mean change in daily hunger questionnaire scores for participants \< 12 years of age with obesity in treatment with setmelanotide was evaluated. Hunger was assessed daily using a Daily Hunger Questionnaire with a pictorial (smiley face) version of the Likert rating scale with scores ranged from 0 to 4, with 0 = not hungry at all and 4 = hungriest possible.

    Time frame: Baseline, Month 3

  6. Number of Participants With Shifts From Baseline in Global Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged ≥ 12 Years

    For participants ≥ 12 years of age, the following question was asked using the Global Hunger Questionnaire: Overall, how would you rate the hunger you experience now? Possible responses were: No hunger; Mild hunger; Moderate hunger; Severe hunger; and Not answered.

    Time frame: Baseline, Month 3

  7. Number of Participants With Shifts From Baseline in Global Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged < 12 Years

    For participants \< 12 years of age, the following question was asked to parents or caregivers of participants using the Global Hunger Questionnaire: How hungry is your child acting now? Possible responses were: Not hungry at all; A little hungry; Moderately hungry; Extremely hungry; and Not answered.

    Time frame: Baseline, Month 3

  8. Percent Change From Baseline in Waist Circumference After 3 Months of Setmelanotide Treatment

    Waist circumference (cm) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. All measurements were single measures. Waist circumference was measured when participants were in fasting condition and at approximately the same time at each visit.

    Time frame: Baseline, Month 3

07

Results

Posted Aug 18, 2023

Participant flow

Of the 218 participants screened, 213 participants were enrolled in the study.

Participant flow — Overall Study
Milestone16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 Cohort
Started194104933527221232
Completed1927372222013922
Not completed0231211379310
Withdrew: Withdrawal by subject0205623104
Withdrew: Withdrawal by parent/guardian0011000011
Withdrew: Other0020200010
Withdrew: Adverse event0003213802
Withdrew: Death0001000000
Withdrew: Lack of efficacy0001000000
Withdrew: Lost to follow-up0001001002
Withdrew: Non-compliance with study drug0000000010
Withdrew: Physician decision0000100000
Withdrew: Protocol violation0000000001

Outcome measures

PrimaryNumber of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment
Time frame:
Baseline to Month 3
Reported as:
Count of participants · Participants
Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment
Participants16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 Cohort
Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment637710014819
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE (also referred to as an adverse experience) could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. TEAEs were defined as AEs reported after dosing on Day 1.

Time frame:
From first dose up to Month 16
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Participants16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 Cohort
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)194104933527211229
SecondaryChange From Baseline in Body Weight After 3 Months of Setmelanotide Treatment
Time frame:
Baseline, Month 3
Reported as:
Mean · kg
Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment
kg16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 Cohort
Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment-2.58 ± 4.886-5.16 ± 3.860-4.61 ± 7.771-1.26 ± 4.851-4.74 ± 7.689-0.11 ± 2.432-7.24 ± 6.657-3.98 ± 5.164-0.14 ± 2.805-3.96 ± 4.370
SecondaryPercent Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment
Time frame:
Baseline, Month 3
Reported as:
Mean · percent change
Percent Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment
percent change16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 Cohort
Percent Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment-2.19 ± 3.685-6.38 ± 5.043-4.19 ± 5.579-0.75 ± 4.291-3.50 ± 5.817-0.31 ± 1.772-5.57 ± 5.170-2.92 ± 3.834-0.00 ± 3.651-3.34 ± 3.607
SecondaryChange From Baseline in Daily Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged ≥ 12 Years

The mean change in daily hunger questionnaire scores for participants ≥ 12 years of age with obesity in treatment with setmelanotide was evaluated. On the Daily Hunger Questionnaire, each of the 3 items (average hunger in the last 24 hours, most/worst hunger in the last 24 hours, and morning hunger) was assessed daily and scored separately using a numeric rating score for each from 0 to 10, with 0 = not hungry at all and 10 = hungriest possible.

Time frame:
Baseline, Month 3
Reported as:
Mean · units on a scale
Change From Baseline in Daily Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged ≥ 12 Years
units on a scale16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 Cohort
Baseline: Hunger Score on Average Last 24 hours6.11 ± 2.1025.07 ± 1.8606.37 ± 1.7195.74 ± 1.9155.73 ± 2.1788.07 ± 1.3486.32 ± 2.0626.66 ± 1.966—6.04 ± 2.049
Change at Month 3: Hunger Score on Average Last 24 hours-2.57 ± 2.602-1.23 ± 2.739-3.21 ± 2.858-2.50 ± 2.278-2.71 ± 1.946-3.21 ± 2.525-3.12 ± 1.911-2.78 ± 2.639—-2.47 ± 2.003
Baseline: Hunger Score at Most Hungry Last 24 hours7.23 ± 2.1686.06 ± 2.1857.50 ± 1.4076.84 ± 1.8666.95 ± 2.2818.82 ± 0.9367.45 ± 2.3767.42 ± 1.870—6.91 ± 1.952
Change at Month 3: Hunger Score at Most Hungry Last 24 hours-2.85 ± 2.561-2.27 ± 3.656-4.00 ± 2.717-2.91 ± 2.155-3.00 ± 2.264-4.07 ± 2.929-3.70 ± 2.501-2.68 ± 2.915—-2.67 ± 2.241
Baseline: Hunger Score in Morning5.24 ± 2.5084.98 ± 3.1875.31 ± 2.7053.99 ± 2.8053.89 ± 2.5897.04 ± 2.4375.14 ± 2.5374.96 ± 2.829—4.60 ± 2.924
Change at Month 3: Hunger Score in Morning-2.34 ± 3.390-3.90 ± 4.195-3.14 ± 3.173-2.14 ± 2.914-2.85 ± 2.084-2.36 ± 1.111-3.15 ± 1.781-3.09 ± 1.961—-1.88 ± 1.942
SecondaryChange From Baseline in Daily Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged < 12 Years

The mean change in daily hunger questionnaire scores for participants \< 12 years of age with obesity in treatment with setmelanotide was evaluated. Hunger was assessed daily using a Daily Hunger Questionnaire with a pictorial (smiley face) version of the Likert rating scale with scores ranged from 0 to 4, with 0 = not hungry at all and 4 = hungriest possible.

Time frame:
Baseline, Month 3
Reported as:
Mean · units on a scale
Change From Baseline in Daily Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged < 12 Years
units on a scale16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 Cohort
Baseline: Hunger Right Now2.32 ± 0.741——2.02 ± 1.300——2.17 ± 1.4431.87 ± 0.125——
Change at Month 3: Hunger Right Now-1.57 ± 0.261——-0.72 ± 1.346——-1.55 ± 0.910-1.44 ± 0.387——
SecondaryNumber of Participants With Shifts From Baseline in Global Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged ≥ 12 Years

For participants ≥ 12 years of age, the following question was asked using the Global Hunger Questionnaire: Overall, how would you rate the hunger you experience now? Possible responses were: No hunger; Mild hunger; Moderate hunger; Severe hunger; and Not answered.

Time frame:
Baseline, Month 3
Reported as:
Number · participants
Number of Participants With Shifts From Baseline in Global Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged ≥ 12 Years
participants16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 Cohort
No hunger (Baseline) - No hunger (Month 3)2001200001
No hunger (Baseline) - Mild hunger (Month 3)0012000001
No hunger (Baseline) - Moderate hunger (Month 3)0001100001
No hunger (Baseline) - Severe hunger (Month 3)0000000000
No hunger (Baseline) - Not answered (Month 3)0000000000
Mild hunger (Baseline) - No hunger (Month 3)0002302314
Mild hunger (Baseline) - Mild hunger (Month 3)1225004015
Mild hunger (Baseline) - Moderate hunger (Month 3)1002000011
Mild hunger (Baseline) - Severe hunger (Month 3)0000100000
Mild hunger (Baseline) - Not answered (Month 3)0000000000
Moderate hunger (Baseline) - No hunger (Month 3)2001001110
Moderate hunger (Baseline) - Mild hunger (Month 3)4044514313
Moderate hunger (Baseline) - Moderate hunger (Month 3)2002100002
Moderate hunger (Baseline) - Severe hunger (Month 3)0000000000
Moderate hunger (Baseline) - Not answered (Month 3)0000000000
Severe hunger (Baseline) - No hunger (Month 3)1011102100
Severe hunger (Baseline) - Mild hunger (Month 3)1105101202
Severe hunger (Baseline) - Moderate hunger (Month 3)1001101020
Severe hunger (Baseline) - Severe hunger (Month 3)0000002010
Severe hunger (Baseline) - Not answered (Month 3)0000000000
Not answered (Baseline) - No hunger (Month 3)0000000000
Not answered (Baseline) - Mild hunger (Month 3)0000000000
Not answered (Baseline) - Moderate hunger (Month 3)0000000000
Not answered (Baseline) - Severe hunger (Month 3)0000000000
Not answered (Baseline) - Not answered (Month 3)0000000000
SecondaryNumber of Participants With Shifts From Baseline in Global Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged < 12 Years

For participants \< 12 years of age, the following question was asked to parents or caregivers of participants using the Global Hunger Questionnaire: How hungry is your child acting now? Possible responses were: Not hungry at all; A little hungry; Moderately hungry; Extremely hungry; and Not answered.

Time frame:
Baseline, Month 3
Reported as:
Number · participants
Number of Participants With Shifts From Baseline in Global Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged < 12 Years
participants16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 Cohort
Not hungry at all (Baseline) - Not hungry at all (Month 3)0——1—000—0
Not hungry at all (Baseline) - A little hungry (Month 3)0——0—000—0
Not hungry at all (Baseline) - Moderately hungry (Month 3)0——0—000—0
Not hungry at all (Baseline) - Extremely hungry (Month 3)0——1—000—0
Not hungry at all (Baseline) - Not answered (Month 3)0——0—000—0
A little hungry (Baseline) - Not hungry at all (Month 3)0——0—000—0
A little hungry (Baseline) - A little hungry (Month 3)1——1—121—0
A little hungry (Baseline) - Moderately hungry (Month 3)0——1—000—0
A little hungry (Baseline) - Extremely hungry (Month 3)0——0—000—0
A little hungry (Baseline) - Not answered (Month 3)0——0—000—0
Moderately hungry (Baseline) - Not hungry at all (Month 3)0——0—000—0
Moderately hungry (Baseline) - A little hungry (Month 3)0——0—000—0
Moderately hungry (Baseline) - Moderately hungry (Month 3)0——0—001—0
Moderately hungry (Baseline) - Extremely hungry (Month 3)0——0—000—0
Moderately hungry (Baseline) - Not answered (Month 3)0——0—000—0
Extremely hungry (Baseline) - Not hungry at all (Month 3)0——0—000—1
Extremely hungry (Baseline) - A little hungry (Month 3)1——2—000—1
Extremely hungry (Baseline) - Moderately hungry (Month 3)0——0—000—0
Extremely hungry (Baseline) - Extremely hungry (Month 3)0——1—000—0
Extremely hungry (Baseline) - Not answered (Month 3)0——0—000—0
Not answered (Baseline) - Not hungry at all (Month 3)0——0—000—0
Not answered (Baseline) - A little hungry (Month 3)0——0—000—0
Not answered (Baseline) - Moderately hungry (Month 3)0——0—000—0
Not answered (Baseline) - Extremely hungry (Month 3)0——0—000—0
Not answered (Baseline) - Not answered (Month 3)0——0—000—0
SecondaryPercent Change From Baseline in Waist Circumference After 3 Months of Setmelanotide Treatment

Waist circumference (cm) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. All measurements were single measures. Waist circumference was measured when participants were in fasting condition and at approximately the same time at each visit.

Time frame:
Baseline, Month 3
Reported as:
Mean · percent change
Percent Change From Baseline in Waist Circumference After 3 Months of Setmelanotide Treatment
percent change16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 Cohort
Percent Change From Baseline in Waist Circumference After 3 Months of Setmelanotide Treatment-1.00 ± 6.250-6.60 ± 6.828-4.92 ± 7.191-0.61 ± 11.311-1.09 ± 8.2505.11 ± 8.412-5.59 ± 6.554-4.91 ± 8.495-3.83 ± 8.543-2.88 ± 4.632

Adverse events

Collected over From first dose up to Month 16. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
16p11.2 Cohort0/19 (0%)1/19 (5.3%)19/19 (100%)
AS Cohort0/4 (0%)0/4 (0%)4/4 (100%)
BBS Cohort0/10 (0%)1/10 (10%)10/10 (100%)
MC4R Cohort1/49 (2%)1/49 (2%)48/49 (98%)
POMC/PCSK1/LEPR Heterozygous Cohort0/33 (0%)1/33 (3%)33/33 (100%)
POMC/PCSK1/LEPR Composite Heterozygous Cohort0/5 (0%)1/5 (20%)5/5 (100%)
POMC/PCSK1/LEPR Compound Heterozygous Cohort0/27 (0%)2/27 (7.4%)27/27 (100%)
SH2B1 Cohort0/22 (0%)0/22 (0%)21/22 (95.5%)
SMS Cohort0/12 (0%)0/12 (0%)12/12 (100%)
SRC1 Cohort0/32 (0%)0/32 (0%)29/32 (90.6%)
Most frequent serious events
Most frequent serious events
Event16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 Cohort
HypersensitivityImmune system disorders0/190/40/100/490/331/50/270/220/120/32
Rotavirus InfectionInfections and infestations0/190/41/100/490/330/50/270/220/120/32
Melanocytic NaevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/190/40/100/490/330/50/270/220/120/32
DiverticulitisInfections and infestations0/190/40/100/490/330/51/270/220/120/32
Typical Aura Without HeadacheNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/190/40/100/490/330/51/270/220/120/32
Acute Myocardial InfarctionCardiac disorders0/190/40/101/491/330/50/270/220/120/32
Gastrointestinal HaemorrhageGastrointestinal disorders0/190/40/100/491/330/50/270/220/120/32
Most frequent other events
Showing 10 of 361
Most frequent other events
Event16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 Cohort
Injection Site PruritusGeneral disorders5/192/49/103/498/331/54/272/221/120/32
Skin HyperpigmentationSkin and subcutaneous tissue disorders17/193/48/1040/4919/333/521/2716/2210/1223/32
NauseaGastrointestinal disorders9/191/43/1012/4914/334/513/2713/222/1211/32
Injection Site OedemaGeneral disorders0/190/47/100/492/331/50/270/221/120/32
Injection Site ErythemaGeneral disorders4/190/46/104/498/332/54/271/220/120/32
Injection Site IndurationGeneral disorders2/190/45/103/493/330/50/270/221/120/32
Viral Upper Respiratory Tract InfectionInfections and infestations0/192/40/100/490/330/50/270/220/120/32
HeadacheNervous system disorders9/190/41/1010/498/331/513/2710/221/127/32
VomitingGastrointestinal disorders1/190/42/107/494/332/56/276/220/124/32
InsomniaPsychiatric disorders3/190/40/102/493/332/51/271/220/121/32

Baseline characteristics

The Full Analysis Set (FAS) included all participants who received at least 1 dose of study drug and had baseline weight data.

Age, Continuous
Age, Continuous(years)16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 CohortTotal
Mean21.4 ± 14.5816.0 ± 3.7422.5 ± 14.7122.4 ± 15.2836.1 ± 17.2340.4 ± 19.6230.7 ± 20.1633.6 ± 17.8819.4 ± 8.1031.3 ± 17.1328.1 ± 17.30
Sex: Female, Male
Sex: Female, Male(Participants)16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 CohortTotal
Female13362722418151025143
Male61422111972770
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 CohortTotal
Hispanic or Latino101320022314
Not Hispanic or Latino13484031525191029184
Unknown or Not Reported501600210015
Race (NIH/OMB)
Race (NIH/OMB)(Participants)16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 CohortTotal
American Indian or Alaska Native00000001001
Asian01000011003
Native Hawaiian or Other Pacific Islander00000000000
Black or African American011351051623
White15293828423131024166
More than one race00000000000
Unknown or Not Reported400800321220
Body Weight
Body Weight(kilograms (kg))16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 CohortTotal
Mean113.62 ± 38.48987.28 ± 16.360128.04 ± 28.631117.87 ± 32.339143.04 ± 30.492139.05 ± 30.957122.08 ± 43.315129.06 ± 39.48092.48 ± 24.556124.07 ± 33.717122.98 ± 36.142
Waist Circumference
Waist Circumference(centimeters (cm))16p11.2 CohortAS CohortBBS CohortMC4R CohortPOMC/PCSK1/LEPR Heterozygous CohortPOMC/PCSK1/LEPR Composite Heterozygous CohortPOMC/PCSK1/LEPR Compound Heterozygous CohortSH2B1 CohortSMS CohortSRC1 CohortTotal
Mean116.84 ± 22.179109.75 ± 14.523126.20 ± 19.344122.52 ± 19.697137.95 ± 18.529134.00 ± 19.038128.52 ± 28.772130.28 ± 23.029110.14 ± 11.807123.10 ± 21.101125.63 ± 22.162
08

Study locations

58 sites
  • Synexus Clinical Research US, Inc. - Simon Williamson Clinic, PC
    Birmingham, Alabama 35211, United States
  • Synexus Clinical Research US, Inc. - Phoenix Southeast
    Chandler, Arizona 85224, United States
  • Synexus Clinical Research US, Inc. - Central Arizona Medical Associates, PC
    Mesa, Arizona 85206, United States
  • Honor Health Research Institute
    Scottsdale, Arizona 85258, United States
  • Axis Clinical Trials-Downtown
    Los Angeles, California 90017, United States
  • Axis Clinical Trials Headquarters
    Los Angeles, California 90036, United States
  • San Diego Wake Research
    San Diego, California 92108, United States
  • Anschutz Health and Wellness Center University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Division of Endocrinology and Diabetes Children's National Hospital
    Washington, District of Columbia 20010, United States
  • University of Florida College of Medicine
    Gainesville, Florida 32610, United States
  • AXIS South Florida Clinical Trials
    Hialeah, Florida 33016, United States
  • Florida Hospital
    Orlando, Florida 32804, United States
  • Synexus Clinical Research US, Inc. - St. Petersburg
    Pinellas Park, Florida 33781, United States
  • Synexus Clinical Research US, Inc. - Chicago
    Chicago, Illinois 60602, United States
  • Maine Medical Partners
    Portland, Maine 04102, United States
  • NIH Hatfield Clinical Research Center
    Bethesda, Maryland 20892, United States
  • Baystate Medical Center
    Springfield, Massachusetts 01107, United States
  • University of Michigan Medicine
    Ann Arbor, Michigan 48105, United States
  • Precision Medicine for Obesity Research: Gastroenterology & Hepatology Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University St. Louis
    Saint Louis, Missouri 63110, United States
  • Impact Clinical Trials
    Las Vegas, Nevada 89106, United States
  • AXIS New York Clinical Trials
    Brooklyn, New York 11201, United States
  • University at Buffalo
    Buffalo, New York 14203, United States
  • AXIS Clinical Trials
    New York, New York 10022, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10025, United States
  • Columbia University
    New York, New York 10032, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Wake Research Inc.
    Raleigh, North Carolina 27612, United States
  • Synexus Clinical Research US, Inc. - Akron
    Akron, Ohio 44311, United States
  • Synexus Clinical Research US, Inc. - Cincinnati
    Cincinnati, Ohio 45236, United States
  • Synexus Clinical Research US, Inc. - Columbus
    Columbus, Ohio 43016, United States
  • Obesity Institute, Geisinger Clinic
    Danville, Pennsylvania 17822, United States
  • Childrens Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Synexus Clinical Research US, Inc. - Primary Care Associates, PC
    Anderson, South Carolina 29621, United States
  • Wake Research TN
    Chattanooga, Tennessee 37421, United States
  • Le Bonheur Children's Hospital
    Memphis, Tennessee 38103, United States
  • Vanderbilt University School of Medicine
    Nashville, Tennessee 37212-3157, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Synexus Clinical Research US, Inc. - Plano
    Plano, Texas 75093, United States
  • Synexus Clinical Research US, Inc. - San Antonio
    San Antonio, Texas 78229, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Seattle Children's Research Institute
    Seattle, Washington 98101, United States
  • Marshfield Clinic Research Institute
    Marshfield, Wisconsin 54449, United States
  • University of Alberta
    Edmonton, T6G 2E1, Canada
  • Hopital Trousseau - Nutrition et Gastroentérologie
    Paris, 75012, France
  • Hopital de la Pitié-Salpêtrière
    Paris, 75013, France
  • Service de pédiatrie CHU de la Réunion - Hôpital Félix Guyon
    Saint-Denis, 97405, France
  • Charité Berlin
    Berlin, 13354, Germany
  • University of Leipzig
    Leipzig, 04103, Germany
  • University of Ulm
    Ulm, 89075, Germany
  • University General Hospital of Patras
    Río, Patras 26504, Greece
  • Edmond and Lily Safra Children's Hospital
    Ramat Gan, 52621, Israel
  • Erasmus MC
    Rotterdam, 3015 CE, Netherlands
  • Hospital Infantil Universitario Niño Jesús
    Madrid, 65 28009, Spain
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, B15 2TH, United Kingdom
  • Addenbrooke's Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • Hammersmith Hospital
    London, W12 0NN, United Kingdom
  • Hammersmith Hospital
    London, United Kingdom
09

References and documents

Publications

  • Meyer JR, Krentz AD, Berg RL, Richardson JG, Pomeroy J, Hebbring SJ, Haws RM. Kidney failure in Bardet-Biedl syndrome. Clin Genet. 2022 Apr;101(4):429-441. doi: 10.1111/cge.14119. PubMed 35112343 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Mar 2022, 60 months.

Results were first posted in Aug 2023, 1 year 5 months after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 60 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2017
First posted
Jan 6, 2017
StartActual
Feb 10, 2017
Primary completionActual
Mar 1, 2022
CompletionActual
Mar 1, 2022
Results first posted
Aug 18, 2023
Last update
Aug 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03013543
Responsible party
Sponsor
First posted
Jan 6, 2017
Start date
Feb 10, 2017
Primary completion
Mar 1, 2022
Completion
Mar 1, 2022
Results posted
Aug 18, 2023
Last update
Aug 18, 2023

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion